These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12848314)

  • 21. New and emerging therapies for sepsis.
    Healy DP
    Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Septic shock; current pathogenetic concepts from a clinical perspective.
    Tsiotou AG; Sakorafas GH; Anagnostopoulos G; Bramis J
    Med Sci Monit; 2005 Mar; 11(3):RA76-85. PubMed ID: 15735579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombin III supplementation in severe sepsis: beneficial effects on organ dysfunction.
    Inthorn D; Hoffmann JN; Hartl WH; Mühlbayer D; Jochum M
    Shock; 1997 Nov; 8(5):328-34. PubMed ID: 9361342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulation inhibitors in the treatment of sepsis.
    Freeman BD; Buchman TG
    Expert Opin Investig Drugs; 2002 Jan; 11(1):69-74. PubMed ID: 11772322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Reversible autonomic dysfunction in a young woman with septic multiple organ dysfunction syndrome].
    Schmidt H; Flieger RR; Hennen R; Tymiec P; Winkler M; Hoyer D; Buerke M; Müller-Werdan U; Werdan K
    Dtsch Med Wochenschr; 2005 Mar; 130(12):648-51. PubMed ID: 15776347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation.
    Jochum M
    Semin Hematol; 1995 Oct; 32(4 Suppl 2):19-32. PubMed ID: 8821206
    [No Abstract]   [Full Text] [Related]  

  • 27. Coagulation abnormalities in acute lung injury and sepsis.
    Abraham E
    Am J Respir Cell Mol Biol; 2000 Apr; 22(4):401-4. PubMed ID: 10745020
    [No Abstract]   [Full Text] [Related]  

  • 28. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
    Rice TW; Bernard GR
    Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The coagulopathy of sepsis: pathophysiology and management.
    Satran R; Almog Y
    Isr Med Assoc J; 2003 Jul; 5(7):516-20. PubMed ID: 12901250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coagulation inhibitor replacement during sepsis: useless?
    Hoffman JN; Faist E
    Crit Care Med; 2000 Sep; 28(9 Suppl):S74-6. PubMed ID: 11007203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current management of septic shock.
    Russel JA
    Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?
    Vallet B
    Crit Care; 2003 Apr; 7(2):130-8. PubMed ID: 12720559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Coagulation inhibitors in severe sepsis: state of the art].
    Fourrier F
    Rev Med Interne; 2003 May; 24(5):295-304. PubMed ID: 12763175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Antithrombin III and Tissue Factor Pathway in the Pathogenesis of Sepsis.
    Sungurlu S; Kuppy J; Balk RA
    Crit Care Clin; 2020 Apr; 36(2):255-265. PubMed ID: 32172812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
    Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
    Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock.
    Balk RA
    Crit Care Clin; 2000 Apr; 16(2):337-52, vii. PubMed ID: 10768085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
    Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
    Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
    Rudis MI; Fish DN
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.